Abstract
Pulmonary hypertension (PH) with interstitial lung diseases (ILDs) often causes intractable conditions. CD26/Dipeptidyl peptidase-4 (DPP4) is expressed in lung constituent cells and may be related to the pathogenesis of various respiratory diseases. We aimed to clarify the functional roles of CD26/DPP4 in PH-ILD, paying particular attention to vascular smooth muscle cells (SMCs). Dpp4 knockout (Dpp4KO) and wild type (WT) mice were administered bleomycin (BLM) intraperitoneally to establish a PH-ILD model. The BLM-induced increase in the right ventricular systolic pressure and the right ventricular hypertrophy observed in WT mice were attenuated in Dpp4KO mice. The BLM-induced vascular muscularization in small pulmonary vessels in Dpp4KO mice was milder than that in WT mice. The viability of TGFβ-stimulated human pulmonary artery SMCs (hPASMCs) was lowered due to the DPP4 knockdown with small interfering RNA. According to the results of the transcriptome analysis, upregulated genes in hPASMCs with TGFβ treatment were related to pulmonary vascular SMC proliferation via the Notch, PI3K-Akt, and NFκB signaling pathways. Additionally, DPP4 knockdown in hPASMCs inhibited the pathways upregulated by TGFβ treatment. These results suggest that genetic deficiency of Dpp4 protects against BLM-induced PH-ILD by alleviating vascular remodeling, potentially through the exertion of an antiproliferative effect via inhibition of the TGFβ-related pathways in PASMCs.
Funding Information
  • JSPS KAKENHI (19K17663, 22K16163, 22H03076, 2019, 2019-G6, JP21gm1210003, 223fa627003h0001, 20FC1027, 23FC1031)
  • GSK Japan Research (19K17663, 22K16163, 22H03076, 2019, 2019-G6, JP21gm1210003, 223fa627003h0001, 20FC1027, 23FC1031)
  • Therapeutics Research Initiative Grant from Chiba University School of Medicine (19K17663, 22K16163, 22H03076, 2019, 2019-G6, JP21gm1210003, 223fa627003h0001, 20FC1027, 23FC1031)
  • AMED-CREST (19K17663, 22K16163, 22H03076, 2019, 2019-G6, JP21gm1210003, 223fa627003h0001, 20FC1027, 23FC1031)
  • Japan Agency for Medical Research and Development (19K17663, 22K16163, 22H03076, 2019, 2019-G6, JP21gm1210003, 223fa627003h0001, 20FC1027, 23FC1031)
  • Intractable Respiratory Diseases and Pulmonary Hypertension Research Group, Ministry of Health, Labor and Welfare, Japan (19K17663, 22K16163, 22H03076, 2019, 2019-G6, JP21gm1210003, 223fa627003h0001, 20FC1027, 23FC1031)

This publication has 46 references indexed in Scilit: